Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certolizumab pegol - UCB

Next Previous
Drug Profile

Certolizumab pegol - UCB

Alternative Names: AutoClicks-Prefilled-Pen; CDP-870; Certolizumab; Cimzia; CIMZIA AutoClicks Prefilled Pen; Cimzia AutoClicks Prefilled Pen; CZP; PHA-738144; Simziya

Latest Information Update: 18 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Developer Astellas Pharma; UCB; University of Pennsylvania; University of Southampton; University of Washington
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Registered Non-radiographic axial spondyloarthritis
  • Phase III Interstitial cystitis; Juvenile rheumatoid arthritis
  • Phase II Ulcerative colitis
  • Discontinued Cognition disorders

Most Recent Events

  • 28 Mar 2024 UCB completes the phase III PASCAL trial in Juvenile rheumatoid arthritis in USA, Canada, Argentina, Brazil, Chile, Mexico and Russia (NCT01550003) (EudraCT2009-018027-33)
  • 27 Jun 2022 UCB Biopharma completes a phase I trial for Rheumatoid Arthritis (Treatment-experienced, In adults, In the elderly) (SC, Injection) (NCT04740814)
  • 04 Jan 2022 Efficacy data of a phase III RAPID-PsA trial in progressive Psoriatic arthritis presented at American College of Rheumatology Convergence 2021 (ACR/ARP-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top